Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Thrombocytosis × pelcitoclax × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 2 Thrombocytosis 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Neuroendocrine Tumors 1 Lymphoma, Non-Hodgkin 1 EGFR Positive Non-small Cell Lung Cancer 1

Interventions

ruxolitinib 3 sonidegib 1 pelcitoclax 1 itacitinib 1 imetelstat 1 N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1 INCB039110 1 GRN163L peptide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04354727 2022-07-12

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Ascentage Pharma Group Inc.

Phase 1/2 Withdrawn

Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡